|  | ![[¹²⁵I]GLP-1-(7-37) (human) [¹²⁵I]GLP-1-(7-37) (human)](https://media.labcompare.com/m/1/vendor/107976-400x300.jpg) |  |  |  |
| Company | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation | Aladdin Scientific Corporation |
| Item | CENPO Human Pre-designed siRNA Set A | [¹²⁵I]GLP-1-(7-37) (human) | Amyloid β-Protein Fragment 25-35 | Proteasome-activating peptide 1 TFA | SHP2 protein degrader-2 |
| Catalog Number | C1466361 | rp175108 | A107853 | P658731 | S648891 |
| Price | Supplier Page | Supplier Page | Supplier Page | Supplier Page | Supplier Page |
| Quantity | 1Set | 5mg, 1mg | 100mg, 5mg, 2mg, 1mg, 25mg | 10mg, 5mg, 50mg, 1mg, 25mg | 50mg, 10mg, 100mg, 5mg, 25mg, 1mg |
| Type | Bioactive Small Molecules | Chelating Agents & Ligands | Chelating Agents & Ligands | Chelating Agents & Ligands | Chelating Agents & Ligands |
| Description | CENPO Human Pre-designed siRNA Set A contains three designed siRNAs for CENPO gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components CENPO siRNA-1: 5 nmol (HPLC) CENPO siRNA-2: 5 nmol (HPLC) CENPO siRNA-3: 5 nmol (HPLC) siRNA Negative Control:CENPO Human Pre-designed siRNA Set A contains three designed siRNAs for CENPO gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components CENPO siRNA-1: 5 nmol (HPLC) CENPO siRNA-2: 5 nmol (HPLC) CENPO siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Inquire | Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40) peptides. It has a β-sheet and β-turn structure. Amino Acid Sequence Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-MetFunctional domain of Aβ required for both neurotrophic and neurotoxic effects... Read More | Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis... Read More | SHP2 protein degrader-2 (SHP2-D26) is a SHP2 protein PROTAC degrader. SHP2 protein degrader-2 reduces expression level of SHP2 in various cancer cells.In VitroSHP2 protein degrader-2 (SHP2-D26) achieves excellent degradation of SHP2 with the DC 50 (the concentration where 50% of the protein has beenSHP2 protein degrader-2 (SHP2-D26) is a SHP2 protein PROTAC degrader. SHP2 protein degrader-2 reduces expression level of SHP2 in various cancer cells.In VitroSHP2 protein degrader-2 (SHP2-D26) achieves excellent degradation of SHP2 with the DC 50 (the concentration where 50% of the protein has been degraded) values of 2.6 nM and 6.0 nM for MV4;11 and KYSE520 cells, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid... Read More |
| Get Quote | Supplier Page | Supplier Page | Supplier Page | Supplier Page | Supplier Page |